MarketCapExport financials
Premier (PINC)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Premier Financial Ratios 2025-2011 | PINC
Brief overview of Premier's valuation multiples
The comparison uses the five latest available annual observations between 2020 and 2025.
The current valuation set is P/E 114.94x (median 70.23x), EV/EBITDA 29.8x (median 14.24x), P/S 7.82x (median 10.67x). The current ratio basket stands about 26.7% below the five-year comparison base. Earnings and risk trends should explain the discount.
Current earnings relative to valuation equal about 0.9% on the 1/P/E measure. This is a valuation reference, not an expected payout.
Current measures of operating quality are ROE 1.2%, ROA 0.6%, ROCE 0.1%. Low capital returns limit the ability to compound value internally.
PEG is 1.73x. Price is well ahead of embedded growth, making market expectations demanding.
The time from paying for inputs to receiving cash fell from 155.2 days to 110.3 days. Cash turnover improved.
Conclusion
Premier's multiples look low against history, but fundamental returns do not yet provide convincing support.
Annual Financial Ratios Premier
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 114.9 | -27.7 | 56.5 | 70.2 | 54.9 | 89.8 | 21.6 | 59.5 | 15.4 | 33.3 | 32.4 | 26.0 | - | - | - | |
P/S |
7.8 | 9.8 | 10.7 | 12.6 | 11.2 | 9.5 | 1.9 | 1.2 | 1.2 | 1.2 | 1.2 | 0.8 | - | - | - |
EPS |
0.2 | 1.1 | 1.5 | 0.5 | 0.6 | 0.4 | -0.1 | 3.6 | 1.5 | 19.3 | -24.2 | -105.8 | 1.3 | 0.6 | - |
EV (Enterprise Value) |
3.54 B | 3.68 B | 2.99 B | 5.54 B | 5.41 B | 6.74 B | 5.65 B | 5.57 B | 5.76 B | 4.94 B | 5.76 B | 4.32 B | 243 M | 336 M | - |
EBITDA per Share |
1.44 | 2.7 | 3.15 | 3.28 | 3.12 | 4.31 | 7.13 | 11.1 | 7.37 | 7.06 | 7.71 | 11.9 | - | - | - |
EV/EBITDA |
29.8 | 14.4 | 7.9 | 14.2 | 13.9 | 5.4 | 5.3 | 3.3 | 5.0 | 3.9 | 4.1 | 2.1 | - | - | - |
PEG |
-6.58 | 1.73 | -2.77 | -7.46 | -5.75 | -15.67 | -0.45 | 0.45 | -0.17 | 0.19 | 0.42 | -0.0 | - | - | - |
P/B |
1.3 | 1.2 | - | 2.0 | 1.9 | 28.9 | -2.7 | -1.4 | -1.1 | -0.7 | -0.4 | -0.3 | - | - | - |
P/CF |
5.1 | 8.0 | 6.7 | 10.2 | 10.4 | 11.5 | 5.7 | 4.8 | 5.4 | 4.7 | 4.3 | 2.4 | - | - | - |
ROE % |
1.17 | -4.34 | 2.26 | 2.86 | 3.46 | 32.24 | -12.66 | -2.33 | -6.82 | -2.13 | -1.24 | -1.15 | - | - | - |
ROA % |
0.58 | -2.51 | - | 1.92 | 2.19 | 1.52 | 4.25 | 1.44 | 4.52 | 2.24 | 2.53 | 2.27 | - | - | - |
ROCE % |
0.07 | 6.45 | 10.46 | 11.56 | 11.52 | 268.28 | 17.45 | 28.96 | 16.41 | 17.39 | 21.11 | 29.53 | - | - | - |
Current Ratio |
2.0 | 2.4 | - | 3.0 | 2.7 | 1.0 | 1.3 | 1.0 | 0.7 | 1.4 | 2.1 | 1.9 | - | - | - |
DSO |
138.9 | 76.7 | 74.4 | 129.7 | 133.1 | 140.0 | 118.3 | 41.0 | 41.8 | 46.3 | 37.2 | 27.6 | - | - | - |
DIO |
- | - | 100.1 | 98.6 | 51.1 | 51.5 | 52.4 | 30.2 | 27.1 | 23.3 | 30.4 | 24.7 | - | - | - |
DPO |
28.6 | 15.3 | 37.3 | 43.3 | 29.0 | 46.1 | 56.0 | 27.5 | 23.0 | 36.7 | 34.6 | 33.2 | - | - | - |
Operating Cycle |
138.9 | 76.7 | 174.6 | 228.3 | 184.2 | 191.5 | 170.7 | 71.3 | 68.8 | 69.6 | 67.6 | 52.3 | - | - | - |
Cash Conversion Cycle |
110.3 | 61.3 | 137.2 | 185.0 | 155.2 | 145.3 | 114.7 | 43.8 | 45.9 | 32.8 | 33.0 | 19.1 | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Financial Ratios Premier
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
0.21 | 0.31 | -1.01 | 0.31 | -1.01 | 0.71 | 0.45 | -0.36 | 0.45 | 0.38 | 0.54 | 0.39 | 0.54 | 0.36 | 0.9 | 0.32 | 0.62 | 0.99 | 1.62 | 0.4 | 0.36 | 1.2 | 0.36 | 1.43 | -6.88 | 11.53 | -6.87 | 11.53 | 11.6 | -12.79 | 11.59 | -12.8 | 5.09 | 6.36 | 5.09 | 6.36 | 8.1 | 1.49 | 8.1 | 1.49 | -1.31 | 12.49 | -1.31 | 12.49 | -0.93 | -11.53 | -0.93 | -11.53 | -114.7 | -0.08 | -114.7 | 0.68 | 0.33 | 0.37 | - | - | - | - | - | - |
EBITDA per Share |
0.67 | 0.72 | -0.67 | 0.72 | -0.67 | 0.64 | 0.82 | -0.4 | 0.8 | 0.76 | 1.03 | 0.8 | 1.03 | 0.78 | 1.81 | 0.75 | 0.91 | 0.84 | 1.75 | 0.78 | 0.81 | 0.88 | 0.81 | 0.88 | 2.45 | 1.94 | 2.45 | 1.94 | 2.26 | 2.4 | 2.24 | 2.38 | 5.37 | 1.91 | 5.37 | 1.91 | 2.02 | 2.03 | 2.02 | 2.03 | 2.2 | 2.28 | 2.2 | 2.28 | 2.25 | 2.39 | 2.25 | 2.39 | 2.2 | 20.9 | 2.2 | 1.07 M | 15.1 | - | - | - | - | - | - | - |
ROE % |
-0.44 | -6.40 | -4.51 | 2.66 | -1.66 | 5.52 | 3.67 | 4.25 | 8.89 | 9.47 | 9.57 | 11.55 | 11.21 | 11.81 | 15.12 | 19.25 | 22.71 | 21.41 | 18.27 | 11.43 | 14.69 | -8.70 | -32.06 | -55.43 | -125.99 | -116.39 | -106.80 | -97.27 | -29.87 | -20.25 | -13.26 | -9.96 | -9.00 | -25.19 | -23.65 | -38.71 | -48.57 | -28.07 | -42.83 | -19.56 | -14.42 | -16.98 | 0.61 | 0.49 | -1.42 | -1.26 | -376.40 | 640399623.98 | 640402721.13 | -375.46 | 640400000.00 | 3096.78 | - | - | - | - | - | - | - | - |
ROA % |
-0.46 | -3.68 | -2.40 | 1.69 | -0.64 | 3.45 | 2.40 | 2.84 | 6.12 | 6.00 | 8.09 | 6.27 | 7.38 | 7.80 | 9.95 | 12.39 | 14.72 | 13.76 | 11.66 | 7.55 | 10.23 | 12.48 | 14.73 | 16.72 | 13.31 | 13.75 | 14.36 | 15.38 | 8.18 | 5.07 | 3.33 | 2.00 | 3.26 | 11.82 | 12.48 | 22.15 | 29.16 | 16.71 | 41.47 | 29.11 | 22.19 | 25.88 | -1.24 | -1.02 | 2.86 | 2.79 | 1.99 | 2.40 | 3098.43 | -0.09 | 1.15 | 3096.78 | - | - | - | - | - | - | - | - |
ROCE % |
0.66 | -6.37 | -6.78 | 1.37 | -4.88 | 3.15 | 3.83 | 4.90 | 11.61 | 12.80 | 12.91 | 15.61 | 15.48 | 15.07 | 15.59 | 15.81 | 16.11 | 15.94 | 15.46 | 11.95 | 11.77 | -19.33 | -41.37 | -72.44 | -148.28 | -131.68 | -122.83 | -106.08 | -37.65 | -54.34 | -49.24 | -66.08 | -66.81 | -44.42 | -42.89 | -20.23 | -18.48 | -15.80 | -14.46 | -11.43 | -9.90 | -9.48 | -9.21 | -9.62 | -10.11 | -9.43 | 85934.36 | 6124985937.02 | 6125064791.54 | 85941.46 | 6124900000.00 | 78851.84 | - | - | - | - | - | - | - | - |
Current Ratio |
2.0 | 2.0 | 2.2 | 2.0 | 2.2 | 2.4 | 2.7 | 2.3 | 2.7 | 2.6 | 2.9 | - | 2.9 | 3.0 | 3.0 | 2.7 | 2.9 | 2.9 | 2.7 | 2.7 | 2.6 | 2.6 | 2.7 | 2.7 | 2.8 | 2.9 | 2.7 | 2.7 | 2.8 | 3.0 | 2.8 | 2.8 | 2.7 | 2.5 | 2.4 | 2.4 | 2.1 | 2.8 | 2.0 | 2.8 | 2.5 | 2.5 | 2.7 | 2.7 | 2.6 | 2.8 | 2.6 | 2.6 | 2.4 | 3.0 | 3.0 | - | - | - | - | - | - | - | - | - |
DSO |
34.0 | 36.5 | 39.7 | 36.5 | 41.0 | 40.6 | 33.2 | 38.7 | 36.6 | 37.8 | 15.3 | 17.1 | 28.7 | 31.9 | 16.2 | 34.6 | 33.3 | 35.2 | 17.5 | 30.0 | 32.2 | 35.1 | 29.1 | 39.7 | 46.4 | 49.2 | 48.0 | 55.1 | 56.3 | 57.5 | 39.2 | 38.3 | 38.3 | 39.0 | 35.4 | 39.8 | 41.4 | 47.4 | 41.4 | 39.2 | 37.7 | 36.3 | 31.0 | 31.3 | 30.7 | 29.6 | 24.7 | 27.1 | 28.6 | 23.3 | 13.2 | - | - | - | - | - | - | - | - | - |
DIO |
- | - | - | - | - | 49.0 | 60.5 | 97.7 | 98.6 | 132.5 | 45.4 | 51.5 | 93.8 | 99.3 | 49.8 | 93.9 | 101.5 | 102.9 | 54.4 | 62.7 | 69.3 | 64.2 | 30.6 | 37.1 | 47.8 | 51.8 | 46.5 | 60.7 | 71.7 | 66.3 | 27.3 | 30.9 | 27.2 | 25.8 | 22.9 | 27.7 | 26.0 | 33.1 | 24.6 | 19.6 | 25.2 | 27.1 | 26.8 | 25.4 | 24.2 | 21.9 | 20.1 | 18.7 | 18.1 | 17.2 | 8.0 | - | - | - | - | - | - | - | - | - |
DPO |
28.7 | 27.8 | 27.4 | 27.8 | 30.7 | 53.2 | 48.9 | 78.9 | 71.1 | 78.2 | 24.0 | 27.2 | 47.3 | 42.6 | 19.6 | 41.9 | 51.2 | 52.1 | 26.3 | 31.8 | 35.0 | 36.9 | 23.6 | 32.4 | 50.4 | 56.1 | 49.6 | 60.9 | 62.4 | 55.6 | 24.8 | 26.5 | 22.1 | 21.5 | 19.5 | 26.9 | 29.6 | 37.6 | 30.1 | 23.7 | 25.2 | 30.9 | 30.5 | 27.9 | 26.6 | 27.4 | 27.0 | 26.4 | 28.8 | 29.4 | 13.7 | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | 34.0 | - | 36.5 | 41.0 | 40.4 | - | 136.4 | 135.2 | - | - | - | 122.5 | 131.2 | 66.1 | 128.5 | 134.8 | 138.1 | 71.9 | 92.7 | 101.5 | 99.3 | 59.7 | 76.8 | 94.2 | 101.0 | 94.5 | 115.8 | 128.0 | 123.9 | 66.5 | 69.3 | 65.5 | 64.7 | 58.4 | 67.5 | 67.5 | 80.5 | 66.0 | 58.8 | 62.9 | 63.4 | 57.8 | 56.7 | 54.9 | 51.5 | 44.8 | 45.8 | 46.7 | 40.5 | 21.2 | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | 5.3 | - | 8.7 | 10.3 | -21.6 | - | 57.5 | 64.1 | - | - | - | 75.2 | 88.6 | 46.5 | 86.6 | 83.7 | 86.0 | 45.5 | 60.9 | 66.4 | 62.5 | 36.1 | 44.4 | 43.8 | 44.9 | 44.8 | 55.0 | 65.6 | 68.2 | 41.6 | 42.8 | 43.4 | 43.2 | 38.9 | 40.6 | 37.9 | 42.9 | 35.9 | 35.1 | 37.7 | 32.5 | 27.3 | 28.8 | 28.4 | 24.1 | 17.8 | 19.4 | 17.9 | 11.1 | 7.5 | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Multiples are an important financial analysis tool for the company Premier, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Health information services industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Tabula Rasa HealthCare
TRHC
|
- | - | $ 255 M |  USA |
 |
Change Healthcare
CHNG
|
- | - | $ 9.03 B | USA |
 |
Cerner Corporation
CERN
|
- | - | $ 27.9 B | USA |
 |
Accolade
ACCD
|
- | 0.29 % | $ 206 M | USA |
 |
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | USA |
 |
Covetrus
CVET
|
- | - | $ 2.94 B | USA |
 |
10x Genomics
TXG
|
$ 62.02 | -1.4 % | $ 7.74 B | USA |
 |
Veeva Systems
VEEV
|
$ 305.03 | -0.17 % | $ 49.9 B | USA |
 |
HealthStream
HSTM
|
$ 28.91 | 0.42 % | $ 868 M | USA |
 |
SCWorx Corp.
WORX
|
$ 1.31 | -2.21 % | $ 9.53 M | USA |
 |
Zhongchao
ZCMD
|
$ 0.97 | 0.86 % | $ 3.32 M |  China |
 |
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | USA |
 |
R1 RCM
RCM
|
- | - | $ 3.81 B | USA |
 |
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | USA |
 |
NextGen Healthcare
NXGN
|
- | - | $ 1.6 B | USA |
 |
iCAD
ICAD
|
- | - | $ 102 M | USA |
 |
So-Young International
SY
|
$ 2.11 | 4.98 % | $ 164 M | China |
 |
OptimizeRx Corporation
OPRX
|
$ 8.85 | -5.35 % | $ 164 M | USA |
 |
American Well Corporation
AMWL
|
$ 12.34 | 2.66 % | $ 198 M | USA |
 |
Evolent Health
EVH
|
$ 4.96 | 2.09 % | $ 566 M | USA |
 |
GoodRx Holdings
GDRX
|
$ 3.61 | 1.98 % | $ 1.29 B | USA |
 |
Castlight Health, Inc.
CSLT
|
- | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
- | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
- | - | $ 6.37 B | USA |
 |
Health Catalyst
HCAT
|
$ 1.45 | 0.35 % | $ 101 M | USA |
 |
HealthEquity
HQY
|
$ 102.96 | -0.56 % | $ 8.87 B | USA |
 |
Omnicell
OMCL
|
$ 35.73 | -0.47 % | $ 1.64 B | USA |
 |
Progyny
PGNY
|
$ 36.47 | 0.11 % | $ 3.11 B | USA |
 |
Schrödinger
SDGR
|
$ 31.63 | -2.41 % | $ 2.32 B | USA |
 |
Teladoc Health
TDOC
|
$ 8.96 | 0.17 % | $ 1.58 B | USA |
 |
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | USA |
 |
Phreesia
PHR
|
$ 12.83 | -2.28 % | $ 766 M | USA |
 |
Akerna Corp.
KERN
|
- | - | $ 161 M | USA |
 |
MTBC
MTBC
|
- | -0.58 % | $ 51.7 M | USA |
 |
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | USA |